Work

A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B receptor, and morphine in recreational opioid users

Year: 2023

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Psychopharmacology

DOI: 10.1177/02698811231167852

Authors: Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, Gerard J Marek

Institutions: Astellas Pharma (United States), Altasciences Clinical Research Vince & Associates, Gilgamesh Pharma (United States)

Language: English

Topic: Opioid Use Disorder Treatment

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institute on Drug Abuse

Award: Evaluation of the Safety and Efficacy of a New Oral Small Molecule GABA-B Receptor Positive Allosteric Modulator (PAM) as an Add-on Maintenance Therapy for Opioid Use Disorder (OUD)

OpenAlex ID: W4367054698

FWCI: 1.274

Cites: 32

Cited by: 5

Related to: 10